large B-cell lymphoma

Summary

large B-cell lymphoma (MONDO:0968974) is a cancer and 86 clinical trials. Top therapeutic interventions include fludarabine phosphate, glofitamab, and axicabtagene ciloleucel. A subtype of B-cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 86

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	large B-cell lymphoma
Mondo ID	MONDO:0968974
DOID	DOID:0081452
UMLS	C5212315
MedGen	1853176
GARD	0027036
Is cancer (heuristic)	yes

Disease family

This is a subtype of B-cell neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › large B-cell lymphoma

Related subtypes (4): lymphoplasmacytic lymphoma, neoplasm of mature B-cells, B-cell non-Hodgkin lymphoma, high-grade B-cell lymphoma double-hit/triple-hit

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 86.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	34
PHASE1	17
PHASE1/PHASE2	14
Not specified	12
PHASE3	7
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05108805	PHASE4	COMPLETED	Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
NCT05429268	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05820841	PHASE3	RECRUITING	Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
NCT06047080	PHASE3	ACTIVE_NOT_RECRUITING	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06356129	PHASE3	ACTIVE_NOT_RECRUITING	Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT07188558	PHASE3	RECRUITING	A Study to Investigate Ronde-cel Versus Investigator’s Choice CD19 CAR T-Cell Therapy
NCT07215585	PHASE3	RECRUITING	AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT00118209	PHASE3	COMPLETED	Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
NCT03642626	PHASE2	ACTIVE_NOT_RECRUITING	MT2017-45: CAR-T Cell Therapy for Heme Malignancies
NCT03960840	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT04661020	PHASE2	RECRUITING	CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
NCT04836507	PHASE1/PHASE2	RECRUITING	Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
NCT04889716	PHASE2	RECRUITING	CAR-T Followed by Bispecific Antibodies
NCT05326243	PHASE1/PHASE2	RECRUITING	Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
NCT05404048	PHASE2	ACTIVE_NOT_RECRUITING	PD-L1 PET-imaging During CAR T-cell Therapy
NCT05464719	PHASE2	RECRUITING	A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05643742	PHASE1/PHASE2	RECRUITING	A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05648019	PHASE2	RECRUITING	CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
NCT05826535	PHASE1/PHASE2	RECRUITING	Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT06045247	PHASE2	RECRUITING	Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06045910	PHASE1/PHASE2	RECRUITING	A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
NCT06071871	PHASE2	RECRUITING	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
NCT06104592	PHASE2	RECRUITING	Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
NCT06167785	PHASE2	RECRUITING	A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
NCT06343311	PHASE1/PHASE2	RECRUITING	T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
NCT06375733	PHASE1/PHASE2	RECRUITING	A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
NCT06479356	PHASE2	RECRUITING	CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
NCT06486051	PHASE2	RECRUITING	A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
NCT06500273	PHASE2	RECRUITING	Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06526793	PHASE2	RECRUITING	Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06533579	PHASE1/PHASE2	RECRUITING	Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06550141	PHASE2	RECRUITING	Emapalumab Prevention of CAR-T Cell Associated Toxicities
NCT06564038	PHASE1/PHASE2	RECRUITING	A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06567366	PHASE2	NOT_YET_RECRUITING	CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
NCT06760156	PHASE2	RECRUITING	Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06811272	PHASE2	RECRUITING	Outpatient Epcoritamab as 2L in NTE R/R DLBCL
NCT06919939	PHASE2	RECRUITING	Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
NCT07126236	PHASE2	RECRUITING	Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
NCT07164469	PHASE2	NOT_YET_RECRUITING	Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
NCT07240194	PHASE2	RECRUITING	The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDARABINE PHOSPHATE	4	10
GLOFITAMAB	4	9
AXICABTAGENE CILOLEUCEL	4	7
EPCORITAMAB	4	5
CYCLOPHOSPHAMIDE ANHYDROUS	4	3
POLATUZUMAB VEDOTIN	4	3
DOXORUBICIN	4	2
EMAPALUMAB	4	2
LONCASTUXIMAB TESIRINE	4	2
MOSUNETUZUMAB	4	2
TAFASITAMAB	4	2
ZANUBRUTINIB	4	2
ACALABRUTINIB	4	1
BREXUCABTAGENE AUTOLEUCEL	4	1
IDECABTAGENE VICLEUCEL	4	1
PEGFILGRASTIM	4	1
RITUXIMAB	4	1
SIROLIMUS	4	1
TISAGENLECLEUCEL	4	1
VINCRISTINE	4	1
GOLCADOMIDE	3	3
FLUDARABINE	3	1
LISOCABTAGENE MARALEUCEL	3	1
MAGROLIMAB	3	1
SUROVATAMIG	2	3
CEMACABTAGENE ANSEGEDLEUCEL	2	1
EFINEPTAKIN ALFA	2	1
POSELTINIB	2	1
RIMIDUCID	2	1
FIANLIMAB DFO ZR-89	1	1